Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | -0.70% | +2.90% | +151.33% |
May. 09 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
May. 09 | Nektar Therapeutics Reiterates Earnings Guidance for the Year 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+151.33% | 261M | C | ||
+42.69% | 749B | C+ | ||
+38.38% | 605B | B | ||
-6.87% | 351B | C+ | ||
+18.74% | 328B | B- | ||
+6.76% | 292B | C+ | ||
+11.19% | 216B | B- | ||
-2.66% | 214B | A+ | ||
+2.64% | 167B | C+ | ||
+6.72% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NKTR Stock
- Ratings Nektar Therapeutics